Mylan, Novartis Settle Spat Over Femara Generic
Novartis Pharmaceutical Corp. has ended its battle with generic-drug maker Mylan Inc. over the patent for the generic version of Novartis' Femara, a drug that treats breast cancer in postmenopausal women,...To view the full article, register now.
Already a subscriber? Click here to view full article